Magic bullets ? monoclonal antibodies in acute leukaemias and non-Hodgkin lymphomas treatment

• Authors: W. Luczynski , M. Krawczuk-Rybak
• Languages of publication: PL

Abstracts

EN

Because of high percent of failures in haematologic malignancies treatment there is a need of discovering new drugs. One of the new approaches are monoclonal antibodies, which target specific cluster differentiation antigens on tumor cells. Rituximab is an anti-CD20 antibody used in non-Hodgkin lymphoma, alemtuzumab - in B chronic lymphocytic leukaemia, gemtuzumab ozogamicin ? in non-lymphoblastic leukaemia, tositumomab and ibritumomab are monoclonal antibodies binded with radiopharmaceutics and are used in non-Hodgkin lymphomas.

Keywords

EN

LEUKAEMIA; MONOCLONAL ANTIBODY; NON-HODGKIN LYMPHOMA

Discipline

• EXPERIMENTAL_BIOLOGY_&_MEDICINE: EXPERIMENTAL BIOLOGY & MEDICINE

• Publisher: Index Copernicus International
• Journal: Postępy Higieny i Medycyny Doświadczalnej
• Year: 2002
• Volume: 56
• Issue: 6
• Pages: 789-801

Contributors

author

W. Luczynski

author

M. Krawczuk-Rybak

• Document Type: ARTICLE
• Publication order reference: W. Luczynski, Klinika Onkologii Dzieciecej Akademii Medycznej, ul. Waszyngtona 17, 15-274 Bialystok, Poland